Display search results for ** instead (33 products)

Showing 1-10 of 33

In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...

USD 450.00

USD 337.50 save 25 %

Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...

USD 450.00

USD 337.50 save 25 %

As the Wearables sector continues to explode in interest in the healthcare space in terms of potential hard benefit to consumers, providers, and vendors across the value chain of connected healthcare, areas are expanding in launches besides that of activity tracking. The following Vital Signs presents analyst discussion regarding brain wearables in...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.

USD 450.00

USD 337.50 save 25 %

11 Jul 2014  |  Global

Will Virtual CROs and Integrated Business Models Rule the Road

Insights into the innovative steps taken by CROs and pharmaceutical companies in the race for excellence and low-cost trials

This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 33